EA013878B1 - Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения - Google Patents

Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения Download PDF

Info

Publication number
EA013878B1
EA013878B1 EA200801172A EA200801172A EA013878B1 EA 013878 B1 EA013878 B1 EA 013878B1 EA 200801172 A EA200801172 A EA 200801172A EA 200801172 A EA200801172 A EA 200801172A EA 013878 B1 EA013878 B1 EA 013878B1
Authority
EA
Eurasian Patent Office
Prior art keywords
zeo
oom16
binding
binding specificity
ecec
Prior art date
Application number
EA200801172A
Other languages
English (en)
Russian (ru)
Other versions
EA200801172A1 (ru
Inventor
Ольга Игнатович
Стив Холмс
Роланд Бекманн
Хайкун Лиу
Рудольф М.Т. Де Вильдт
Лорен С. Джесперс
Майкл Стьюард
Армин Сепп
Малгорзата Пьюпекка
Original Assignee
Домантис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Домантис Лимитед filed Critical Домантис Лимитед
Publication of EA200801172A1 publication Critical patent/EA200801172A1/ru
Publication of EA013878B1 publication Critical patent/EA013878B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA200801172A 2005-12-06 2006-12-05 Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения EA013878B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11
PCT/GB2006/004559 WO2007066106A1 (en) 2005-12-06 2006-12-05 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor

Publications (2)

Publication Number Publication Date
EA200801172A1 EA200801172A1 (ru) 2008-12-30
EA013878B1 true EA013878B1 (ru) 2010-08-30

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801172A EA013878B1 (ru) 2005-12-06 2006-12-05 Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения

Country Status (13)

Country Link
US (2) US20100056439A1 (enExample)
EP (1) EP1966242A1 (enExample)
JP (1) JP2009518024A (enExample)
KR (1) KR20080077261A (enExample)
AU (1) AU2006323412A1 (enExample)
BR (1) BRPI0619463A2 (enExample)
CA (1) CA2632417A1 (enExample)
CR (1) CR10024A (enExample)
EA (1) EA013878B1 (enExample)
MA (1) MA30021B1 (enExample)
NO (1) NO20082386L (enExample)
TW (1) TW200804425A (enExample)
WO (1) WO2007066106A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
UY31504A1 (es) * 2007-11-30 2009-07-17 Construcciones de union de antigenos
CA2707986A1 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CA2718480A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
WO2010033249A2 (en) * 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
WO2010046337A2 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for dc-sign
CN102224169A (zh) * 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
JP5901517B2 (ja) * 2009-05-28 2016-04-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合性タンパク質
SG177601A1 (en) * 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EA201390116A1 (ru) * 2010-08-20 2013-09-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Улучшенные связывающие варианты против сывороточного альбумина
EP2853542A1 (en) * 2010-11-24 2015-04-01 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140255471A1 (en) 2013-03-11 2014-09-11 Wake Forest University Health Sciences Method of treating brain tumors
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN105814082A (zh) * 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
CA2974720A1 (en) * 2015-02-06 2016-08-11 University Of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
PL3322734T3 (pl) 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EP3768722A4 (en) * 2018-03-19 2021-12-29 Wuxi Biologics Ireland Limited. Novel anti-egfr antibody polypeptide
CN113874396B (zh) * 2019-03-29 2024-01-05 株式会社绿十字 包含抗间皮素抗体、抗cd3抗体或抗egfr抗体的融合蛋白、包含所述融合蛋白的双特异性或三特异性抗体，及其用途
US12043652B2 (en) 2020-08-28 2024-07-23 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2177950C2 (ru) * 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
RU2003114746A (ru) * 2000-10-20 2004-12-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US20060228355A1 (en) * 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2177950C2 (ru) * 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
RU2003114746A (ru) * 2000-10-20 2004-12-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело

Also Published As

Publication number Publication date
CA2632417A1 (en) 2007-06-14
JP2009518024A (ja) 2009-05-07
MA30021B1 (fr) 2008-12-01
WO2007066106A1 (en) 2007-06-14
US20130041136A1 (en) 2013-02-14
KR20080077261A (ko) 2008-08-21
NO20082386L (no) 2008-08-27
US20100056439A1 (en) 2010-03-04
CR10024A (es) 2008-09-22
TW200804425A (en) 2008-01-16
EP1966242A1 (en) 2008-09-10
EA200801172A1 (ru) 2008-12-30
AU2006323412A1 (en) 2007-06-14
BRPI0619463A2 (pt) 2013-01-08

Similar Documents

Publication Publication Date Title
EA013878B1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
EP4176896B1 (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CN109311991B (zh) Baff-r靶向嵌合抗原受体修饰的t细胞及其用途
JP2021516960A (ja) Ｃｄ７３を標的とする抗体および抗体−薬物複合体、その製造方法と使用
EP4299589A1 (en) Anti-human cd73 antibody and use thereof
CA2960466C (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
CN106459205A (zh) 包含半胱氨酸工程化抗体的轭合化合物
JP2019503709A (ja) ヒト化抗ｃｄ７３抗体
CN117024590A (zh) 抗人b7-h3的单克隆抗体及其应用
EA012622B1 (ru) Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
KR20080090414A (ko) 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법
CN114106190A (zh) 一种抗vegf/pd-l1双特异性抗体及其用途
JP7020656B2 (ja) 組織因子を標的とする抗体、その調製方法及びその使用
WO2014193191A1 (ko) 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
JP2018154641A (ja) 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用
CN119698433A (zh) 抗cd28人源化单域抗体
CA2685182A1 (en) Osteopontin functional epitopes, monoclonal antibody against the epitopes and uses thereof
EP3502141A1 (en) Antibody targeted to tissue factor, preparation method therefor, and use thereof
WO2025067496A1 (zh) 靶向baff-r的全人源抗体、car-t细胞及其应用
JP2018529716A (ja) 癌幹細胞を阻害する組成物及び方法
CN119390838B (zh) 一种靶向ccr7的纳米抗体及其制备与应用
CN115558029B (zh) 靶向pd-1的双特异性抗体、及其制备和应用
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
US20250276077A1 (en) Epha2 antibodies
Wong et al. Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU